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Introduction
Several masses can involve the hypothalamic–
pituitary region, including pituitary adenomas 
(accounting for the majority of cases), crani-
opharyngiomas, Rathke’s cleft cysts, meningi-
omas, other rare brain tumors, or infiltrative, 
infectious, or vascular disease. Pituitary and 
craniopharyngeal duct tumors are the second 
most common group of brain neoplasms in the 
USA (pituitary adenomas most common in 
adults, and craniopharyngiomas in children and 
adolescents), accounting for approximately 16% 
of all primary brain tumors, and being the most 
common affected sites in adolescents and young 
adults (about 32%).1
While the majority of pituitary adenomas are 
nonsecreting, the most frequent hormone-secret-
ing tumors are prolactinomas. While prolactino-
mas are usually treated medically, other secretory 
pituitary adenomas and nonfunctioning sellar and 
parasellar masses that cause mass effect symp-
toms are treated surgically, with a majority of 
cases performed via the transsphenoidal approach. 
Postoperative care by a multidisciplinary team 
including neurosurgeons, endocrinologists, and 
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intensive care teams is a crucial component of the 
management.2 In this review we will analyze the 
possible complications of pituitary surgery and 
their management, focusing on the most frequent: 
hypopituitarism and disorders of water metabo-
lism. Other aspects of long-term surveillance have 
to be tailored according to the cause that led to 
pituitary surgery, and this goes beyond the aim of 
this review. We will focus only on the postsurgical 
management of acromegaly and Cushing disease 
(CD), as failure of primary surgery is a major clin-
ical problem and the decision on the best approach 
for persistent and recurrent disease requires care-
ful evaluation.
Hypopituitarism
One of the most common complications after 
pituitary surgery is hypopituitarism.3 This can be 
partial or total (panhypopituitarism, where all 
hormonal axes are involved), affecting the ante-
rior pituitary, the posterior pituitary, or both. 
Moreover, hypopituitarism can be transient or 
permanent. In this section anterior pituitary hor-
mone deficiency is analyzed, whereas disorders of 
posterior pituitary are reported later in the manu-
script (Table 1).
The risk of postoperative hypopituitarism varies 
according to case series and the etiology, ranging 
from 5–25% for pituitary adenomas, and its 
occurrence varies depending on the operating 
neurosurgeon’s experience.4,5 It peaks to approxi-
mately 75% for craniopharyngiomas.6 For pitui-
tary adenomas, in addition to experience, the size 
and consistency of the tumor, the extension of 
surgical manipulation, and surgery for recurrent 
disease play a role in the occurrence of hypopitui-
tarism.4 The rate of pituitary insufficiency is 
higher for patients operated for CD, and several 
factors can account for this observation: the long-
term need for glucocorticoids (GCs) postopera-
tively for the onset of adrenal insufficiency (AI), a 
larger pituitary manipulation during surgery, and 
the frequent median localization of adrenocorti-
cotropic hormone (ACTH)-secreting pituitary 
adenomas. Finally, endogenous hypercortisolism 
can cause growth hormone (GH) deficiency and 
central hypogonadism per se, and these deficits 
can last for months/years after successful treat-
ment of CD (Table1).
Provided that the postoperative period has been 
uneventful and no acute complications have 
occurred (e.g. central AI; see below), the first 
evaluation for the anterior pituitary function 
should be performed approximately 4–6 weeks 
after pituitary surgery (Table 1). Thyroid axis 
evaluation requires measurement of free thyrox-
ine (T4). Morning serum testosterone is meas-
ured in males, while menstrual history (and 
possibly estradiol measurement) is used in 
premenopausal women. A low or normal follicle-
stimulating hormone (FSH) in a postmenopausal 
woman is a strong indicator of gonadotrophic 
dysfunction suggesting hypopituitarism. GH axis 
can be initially assessed by serum insulin-like 
growth factor (IGF)-1 level. However, unless 
IGF-1 is low in the setting of panhypopituita-
rism, the diagnosis of GH deficiency usually 
requires failure of at least one GH stimulation 
test.3 Patients with a preoperative diagnosis of 
pituitary insufficiency should be reassessed to 
confirm the need of hormonal replacement ther-
apy, as this may improve after adenomectomy in 
a significant percent of patients. Jahangiri and 
colleagues reported normalization of thyroid, 
male gonadal, female gonadal, cortisol and GH 
axis in 36%, 18%, 41%, 29%, and 22% of cases 
respectively.7 Such recovery may take time, 
and it has been demonstrated to be higher at 
1 year compared with 3 months after surgery. 
Interestingly, recovery of adrenal function seems 
more likely in acromegaly patients compared 
with nonfunctioning pituitary adenomas.8,9 The 
timing for further evaluations should be carried 
out upon clinical judgment.
Management of AI
Central AI is the most important anterior pitui-
tary deficit that can follow pituitary surgery. It 
should be promptly recognized, as untreated AI 
can be a life-threatening condition. The status of 
the hypothalamic–pituitary–adrenal axis (HPAA) 
before pituitary surgery accounts for differences 
in the management of central AI perioperatively 
and in the long term (Table 2).10–17
One of the gray areas in the management of non-
CD patients with normal preoperative HPAA is 
whether to give empiric GC coverage after sur-
gery or to apply a steroid-sparing method, giving 
GC only if AI develops. To date, existing evi-
dence has not demonstrated the superiority of 
one of the two strategies, and they are both used 
successfully in clinical practice.2 Whatever 
approach is chosen, we recommend to take sev-
eral factors into account: the percentage of post-
operative AI at each center or each surgeon, the 
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expertise of the team taking care of the patient 
after surgery, the extent of surgery, the postopera-
tive course, and the turnaround time of serum 
cortisol measurements at the institution. Because 
postoperative AI, although relatively rare in those 
with an intact HPAA before surgery who are 
referred to experienced neurosurgeons, remains a 
life-threatening condition if not promptly recog-
nized and treated, we give parenteral hydrocorti-
sone to all patients in the first 24 h after pituitary 
surgery (e.g. 50 mg every 6 h), rapidly tapering to 
the standard oral replacement dose (15–20 mg/
daily) during the following 48 h if surgery is 
uncomplicated. This dose is similar to what was 
recommended in a study looking at urinary free 
cortisol secretion in patients with intact HPAA 
(150 mg/day).18 We then check an AM prehydro-
cortisone dose serum morning cortisol in an out-
patient setting about 1 week after surgery. A level 
<138 nmol/l (5.0 µg/dl) highly likely predicts AI, 
whereas values >414 nmol/l (15.0 µg/dl) virtually 
rule out this diagnosis in all patients.2,14 However, 
different diagnostic cut-off points for morning 
serum cortisol have been proposed by various 
investigators, with the optimal diagnostic cortisol 
cut-off point remaining an issue of debate.
For low (<138 nmol/l, 5.0 µg/dl) or intermediate 
(138–414 nmol/l, 5.0–15.0 µg/dl) values we con-
tinue GC and retest the patients some weeks 
later. It is important to remember that if ACTH 
stimulation test is chosen for further assessment, 
at least 6 weeks from surgery should have passed 
to allow for adrenal atrophy to develop if ACTH 
secretion is abnormal. The standard (250 µg) and 
low (1 µg) dose ACTH stimulation tests have 
similar accuracy in the diagnosis of secondary 
AI,19 with the latter not providing evident benefits 
4–6 weeks after pituitary surgery.20 Management 
of CD will be discussed below.
Disorders of water metabolism
Disruptions in water regulation can be linked to 
anatomic injury to the hypothalamus, pituitary 
stalk, or posterior pituitary gland during surgery. 
This damage alters the physiology of water 
metabolism controlled by the antidiuretic hor-
mone (ADH) (see Figure 1).21–24 These disorders 
of water metabolism can occur due to a decrease 
in ADH release, leading to central diabetes insipi-
dus (DI), or excess ADH release leading to water 
retention and to the syndrome of inappropriate 
ADH secretion (SIADH). Very rarely, a cerebral 
salt-wasting syndrome (CSWS), an ADH-
independent condition, can occur after pituitary 
surgery.
Central DI and SIADH
DI is defined as the concomitant presence of 
inappropriate hypotonic polyuria (urine output > 
3 l/24 h and urine osmolality < 300 mOsm/kg) in 
the presence of high or normal serum sodium.25 
Other causes of postoperative polyuria should be 
considered, including intraoperative administra-
tion of large amounts of fluids, hyperglycemia 
caused or worsened by GC therapy, and, in acro-
megaly patients, a rapid drop in GH levels. The 
presence of both serum hyperosmolality and 
Figure 1. Physiology of ADH release and action. ADH is synthetized in the magnocellular neurons of the 
paraventricular and supraoptic nuclei, transported along the axons of hypothalamic neurons, and stored 
in the posterior pituitary. Its release has two major stimuli, a raise in plasma osmolality and a decrease 
in blood pressure and circulating blood volume. After ADH is secreted in the circulation, it acts both on 
kidneys (by promoting water reabsorption at the renal collecting duct) and on blood vessels (by stimulating 
vasoconstriction).
ADH, antidiuretic hormone.
Therapeutic Advances in Endocrinology and Metabolism 8(3)
40 journals.sagepub.com/home/tae
hypernatremia is highly suggestive for DI, but 
these laboratory alterations can be absent if the 
patient is conscious and has free access to water.26 
Central DI can be transient or permanent, and 
partial or complete, depending on the kind and 
extent of the damage to hypothalamic magnocel-
lular neurons. According to most case series, DI 
is the most common complication after pituitary 
surgery.27 It occurs in approximately 10–30% of 
patients undergoing pituitary surgery, but it per-
sists long term only in 2–7%,4,28,29 with approxi-
mately 50% of patients remitting in 1 week and 
about 80% in 3 months.30 The risk of permanent 
DI is higher in young patients, males, those with 
large intrasellar masses and postoperative CSF 
leak,26,31 in those with a preoperative diagnosis of 
DI,32,33 following surgery for craniopharyngioma 
or Rathke’s cleft cysts,34 and after repeated pitui-
tary surgery (e.g. for CD).29
The onset of polyuria is usually abrupt, occur-
ring within the first 12–24 h after surgery. Acute 
disorders of water metabolism can manifest in a 
triphasic pattern (in approximately 3% of 
patients): an initial polyuric phase, a subsequent 
antidiuretic phase (the patients can temporarily 
concentrate urine and SIADH and hypona-
tremia develops), and a final polyuric phase that 
is usually chronic.35 Persistence of DI implies 
that at least 85–90% of hypothalamic magnocel-
lular neurons have been damaged by surgery. 
Finally, the antidiuretic phase described above 
is sometimes isolated and represents SIADH. 
This temporary, late-onset (peaking 5–8 days 
after surgery) hyponatremia may be heightened 
by concomitant hypocortisolism as patients with 
unreplaced AI may also present with hypona-
tremia.36 Figure 2 reports the pathophysiology 
management of the postoperative disorders of 
water metabolism.
To screen for potential development of postop-
erative DI and SIADH, we recommend measure-
ment of urine output and fluid intake, urine 
specific gravity daily, and serum sodium every 
6–12 h until discharge. For treatment of DI dur-
ing the immediate postoperative period, we rec-
ommend as-needed use of short acting 
subcutaneous vasopressin (rather than desmo-
pressin, DDAVP), with frequent reassessment of 
response and need to avoid administering an 
ADH when a SIADH phase is occurring. We 
favor the use of vasopressin at this stage because 
of its shorter duration of action, in case DI is tran-
sient and it reverts to SIADH. Hyponatremia 
usually develops between postoperative days 
5–8,2 and therefore these patients should rou-
tinely have a serum sodium level check approxi-
mately on postoperative day 6 or 7. Postoperative 
SIADH seems more frequent in patients with car-
diac, renal or thyroid disease, older age and low 
body mass index, and in patients who receive a 
postoperative lumbar drain.37
Given its often transient course, it is important 
not to over-treat early postoperative DI, to reduce 
the risk of precipitating hyponatremia if the sec-
ond SIADH phase were to occur. Finally, patients 
should be instructed to only drink to thirst, and 
periodically (every couple of weeks) stop their DI 
treatment during the 6 months after surgery to 
verify whether they still need it.
Mild (134–125 mmol/l) hyponatremia can be 
treated in outpatient setting with fluid restriction 
and frequent sodium checks, while more severe 
hyponatremia (<125 mmol/l) requires hospitali-
zation with possible short-time use of hypertonic 
saline or ADH receptor antagonist drugs, being 
careful to avoid over-correction.2
CSWS
Very rarely, hyponatremia after pituitary surgery 
may be caused by CSWS, characterized by 
excessive natriuresis and extracellular volume 
depletion. While SIADH is characterized by 
euvolemic hyponatremia (and thus treated opti-
mally by fluid restriction), CSWS is character-
ized by brain natriuretic peptide-mediated 
hypovolemic hyponatremia (and thus managed 
with hypertonic fluid administration). The dif-
ferential diagnosis between SIADH and the rarer 
CSWS is sometimes difficult. Weight (increased/
unchanged in SIADH and decreased in CSWS), 
serum osmolality (decreased in SIADH and 
increased/normal in CSWS), serum protein lev-
els (normal/high in CSWS), and hematocrit 
(low/normal in SIADH and increased in CSWS) 
may help the differential diagnosis.38
Other possible complications
Apart from hypopituitarism and disorders of 
water metabolism, damage to parasellar struc-
tures can lead to other complications after pitui-
tary surgery, including CSF leak, epistaxis, 
damage to the parasellar visual system, and dam-
age to internal carotid arteries. Mortality rate for 
pituitary surgery in the USA is reported between 
A Prete, SM Corsello et al.
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0.2–1.2%, with lower rates in neurosurgical units 
with more experience.4,39
A CSF leak usually manifests as rhino-liquorrhea 
and headache that is typically worse when sitting 
up and improves lining down. It may be associ-
ated with light sensitivity, nausea, and neck 
stiffness. CSF leak usually occurs in 0.5–4% of 
patients undergoing pituitary surgery,4 although 
rates up to 40% have been reported.40 A non-ade-
nomatous disease, the need for surgical revision, 
tumor margins, size and increased consistency 
have been associated to the risk of intra and post-
operative leaks.41,42 CSF leaks have to be promptly 
Figure 2. Pathophysiology and management of water metabolism imbalance after pituitary surgery.
bid, twice a day; ADH, antidiuretic hormone (vasopressin); AVP, arginine vasopressin; DDAVP, desmopressin; IM, 
intramuscular injection; SC, subcutaneous injection; SIADH, syndrome of inappropriate ADH secretion; tid, three times a day.
Therapeutic Advances in Endocrinology and Metabolism 8(3)
42 journals.sagepub.com/home/tae
recognized and treated, as they expose the patient 
to the risk of ascending infectious meningitis 
(Table 3).43,44
Loss of vision or ophthalmoparesis occur in 
approximately 0.5–2.5% of patients undergoing 
pituitary surgery in the USA.4 They can be either 
caused by a direct surgical damage or by postop-
erative compression of optic structures by hemor-
rhage in the surgical bed. Delayed vision loss has 
been described as well, and it is generally attrib-
uted to herniation of the optic chiasm within the 
sella (secondary empty sella).45
Internal carotid artery injury is uncommon (0.5–
1.5% of surgeries), but can lead to massive life-
threatening bleeding.4 Finally, postoperative 
venous thromboembolism can occur, especially 
in patients with CD, who harbor a higher throm-
botic risk that persists for at least 3 months after 
surgery.46 Therefore, postoperative thrombo-
prophylaxis is advised by some authors in patients 
with CD although the optimal drug choice, dos-
ing and durations are unknown.47
Special situations: CD management after 
primary surgery
After primary surgery for CD, the initial remis-
sion rate is between 25–100%.29 Higher remis-
sion rates are observed for magnetic resonance 
imaging (MRI)-visible microadenomas without 
cavernous sinus invasion, and in centers where 
36–40 patients were operated per year.48 
Nonetheless recurrent and persistent disease is a 
major issue, and second-line (and sometimes 
third-line) treatment options have to be consid-
ered, including repeated neurosurgery, radiother-
apy, medical therapy, bilateral adrenalectomy, or 
a combination of these (Figures 3 and 4). The 
recurrence rate after neurosurgery is highly varia-
ble, ranging between 0–51.2% according to case 
series.27,49,50 A recent meta-analysis places the risk 
of recurrence at 10%.51
How to establish CD remission after pituitary 
surgery?
If patients are not administered GCs, frequent 
(every 6 h) serum cortisol levels should be checked 
starting 12 h after completion of surgery. While 
typically serum cortisol nadirs 24–36 h after com-
pletion of surgery, cases of ‘late cure’ are 
reported.52 We start GC therapy when serum cor-
tisol drops below 138 nmol/l (5.0 µg/dl), or 
patients present symptoms of AI. The develop-
ment of AI after pituitary surgery is the most 
immediate sign that neurosurgery has achieved a 
total or near-total resection of corticotroph tumor 
cells (see Table 2). Other biochemical tests can 
be used to confirm remission, and the most com-
monly used are report in Table 4.29,53
Table 3. Management of postoperative CSF leaks.
When to suspect? How to confirm diagnosis? Conservative treatments Operative treatments
•   Clear, watery nose 
discharge (usually 
unilateral)
•   The patient may 
refer salty or 
metallic taste
•   Headache may occur
•   If infectious 
meningitis develops 





•   Physical examination 
(including anterior 
rhinoscopy)
•   Test nose discharge for 
beta-trace or beta2-
transferrin proteins
•   Cranial CT scans can 
help identifying the 
source of CSF leak
•   Bed rest with head and torso 
tilt of 15–30°
•   Stool softeners to avoid 
increased intracranial pressure 
during bowel movements
•   Avoid actions that can lead 
to increased intracranial 
pressure (coughing, sneezing, 
nose blowing, heavy lifting)
•   Lumbar puncture and CSF 
drainage can be useful to 
reduce intracranial pressure. 
This procedure can sometimes 
block CSF leak
•   Some authors suggest giving 
antibiotic prophylaxis to 
prevent meningitis. However, 
there is currently no consensus
•   Surgical repair. When the leak 
is revealed intraoperatively, 
it should be treated 
immediately, otherwise 
surgery via endoscopic 
technique should be planned 
as soon as the CSF leak is 
confirmed
•   Lumbar puncture and 
CSF drainage can help the 
postoperative course
•   If infectious meningitis 
develops treat with intravenous 
antibiotics and GC.
•   The most common bacteria 
causing ascending meningitis 
are H. influenzae and S. 
pneumoniae
ACTH, adrenocorticotropic hormone; AI, adrenal insufficiency; CD, Cushing disease; CSF, cerebrospinal fluid; CT, computed tomography: GC, 
glucocorticoids; HPAA, hypothalamic–pituitary–adrenal axis.
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Morning serum cortisol is the most widely used 
tool to assess CD remission, although late-night 
salivary cortisol and DDAVP provocative test-
ing have recently shown promising results.54,55 
Whatever test is used, it is worth noting that 
they lack reliable accuracy in predicting long-
term CD remission. For example, 10% of 
patients with delayed relapse have very low 
postsurgical morning serum cortisol, and con-
versely, transient normal-to-elevated cortisol 
values in the immediate postoperative period 
are sometimes found in patients who will later 
go into persistent remission.56 Therefore 
patients successfully treated for CD after pitui-
tary surgery require lifelong follow up and 
retesting, according to clinical judgment.
Management of recurrent and persistent CD
The decision regarding the best treatment for 
recurrent and persistent CD is challenging. Several 
options are available, and the decision has to be tai-
lored to each patient, taking into account the sever-
ity of symptoms, comorbidities, neuroimaging, 
surgical risks, desire for pregnancy, response and 
tolerance to medications.57
Surgical reintervention (when feasible) should be 
the first choice in cases of recurrent or persistent 
CD if postoperative MRI shows a clear, resecta-
ble tumor residue.29,53 However, repeated surgery 
is characterized by lower success rate and a higher 
risk of complications (chiefly hypopituitarism, DI 
and CSF leaks) in comparison with primary 
Figure 3. Cured, persistent and recurrent CD.
‘Cured’ CD means that the patient has gone into persistent remission, defined as normalization of the HPAA after 
surgery. ‘Persistent’ CD is defined as sustained hypercortisolism after pituitary surgery. The term ‘recurrent’ CD refers 
to hypercortisolism occurring after transient resolution (up to several years) of the abnormal cortisol secretion. Residual 
corticotroph tumor cells within the pituitary gland or surrounding structures are responsible for both persistent and 
recurrent CD.
ACTH, adrenocorticotropic hormone; CD, Cushing disease; HPAA, hypothalamic–pituitary–adrenal axis.
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Figure 4. Management of patients with CD.
Possible scenarios during management of patients with CD. Lifelong follow up is mandatory for patients in persistent 
remission after first or repeated pituitary surgery, as they can develop disease relapse many years after surgical treatment.
CD, Cushing disease.
Table 4. The most common ways to assess CD remission after neurosurgery.
Tool Description
Postsurgical AI Transient AI is expected after pituitary surgery (see Table 2). The longer duration of 




•   It is the most used test to assess remission after pituitary surgery
•   It is usually performed 1–7 days after surgery (before morning GC administration)
•   Remission is very likely for values <50 nmol/l (1.8 µg/dl)
•   Remission is likely for values <138 nmol/l (5 µg/dl)
•   Persistent disease is likely for values >200 nmol/l (7.2 µg/dl)
Late-night salivary 
cortisol
•   Little but promising data
•   It is usually performed within the first days after surgery
•   Remission is likely for values <1.9 nmol/l (0.7 ng/dl)
•   Recurrence is likely for values >7.4 nmol/l (2.7 ng/dl)
DDAVP testing •   Little but promising data
•   It is usually performed within the first 6 months after surgery
•   10 µg of DDAVP are given as IV bolus, with measurement of plasma ACTH and 
serum cortisol at 0, +15, +30, +45, +60, +90, and +120 min. A blunted response 
of ACTH (<50% over baseline) or cortisol (<20% over baseline) predicts remission
ACTH, adrenocorticotropic hormone; AI, adrenal insufficiency; CD, Cushing disease; DDAVP, desmopressin; GC, gluco-
corticoids; IV, intravenous.
surgery. If reintervention is not a viable option or 
is expected to be unsuccessful (as judged by an 
experienced pituitary surgeon), second-line 
options (medical therapy, radiotherapy or bilat-
eral adrenalectomy) have to be taken into account.
Special situations: acromegaly management 
after primary surgery
Similarly to CD, higher surgical remission rates in 
acromegaly are observed for microadenomas ver-
sus macroadenomas (particularly if extrasellar 
A Prete, SM Corsello et al.
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extension in present), and in more experienced 
surgical hands.58,59 Cure of acromegaly can cause 
significant diuresis, due to the drop of blood lev-
els of GH and IGF-1 that cause fluid retention 
when inappropriately high.60 This has to be taken 
into account in the differential diagnosis if post-
operative polyuria develops.
Although early postoperative measurement of 
GH level can be a good predictor of cure, no 
obvious cut-off level has been identified.61,62 
Conversely, IGF-1 may take several months to 
normalize even in patients who are completely 
cured.63 Serum GH and IGF-1 should be meas-
ured 12 weeks after surgery or later.64 A postop-
erative 75 g oral glucose load showing GH <  
0.4 ng/ml within 2 h is currently considered 
the best test to assess remission in patients 
with abnormal IGF-1 or GH after pituitary 
surgery.65
Up to approximately 50% of acromegaly patients 
show persistence of the disease after pituitary sur-
gery.66 These patients require a multimodal 
approach to control GH excess, and possible 
strategies are repeated neurosurgery, medical 
therapy (somatostatin analogs, dopamine-recep-
tor agonists, and GH-receptor antagonists), and 
radiotherapy.
Conclusion
The postoperative management of patients 
undergoing transsphenoidal pituitary surgery 
requires a multidisciplinary approach involving 
neurosurgeons, endocrinologists, and often 
intensive care teams. A preoperative hormonal 
assessment will help guide management deci-
sions in the perioperative period, and intra and 
postoperative complications have to be promptly 
diagnosed and treated as to improve patient’s 
outcomes and prognosis. Most complications 
resolve in the short term, but some persist and 
will require lifelong surveillance and treatment. 
In the light of such a multifaceted picture, we 
strongly suggest to refer patients requiring 
transsphenoidal surgery to tertiary centers 
where neurosurgeons, endocrinologists, and 
neurointensivists have the expertise to deal with 
these diseases.
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